Key Points
- CEO Fred Aslan sold 23,463 Artiva Biotherapeutics shares at an average price of $7.20, generating approximately $168,934 and reducing his ownership by 1.52% to 1.52 million shares. The sale followed another disposal of 61,696 shares worth about $422,001 the previous day.
- Artiva shares opened at $7.00, well below their 50-day and 200-day moving averages of $9.96 and $9.24, respectively. The company remains unprofitable, with analysts expecting a full-year loss of $2.62 per share.
- Despite insider selling, analyst sentiment remains broadly positive: the stock has a “Moderate Buy” consensus rating and an average price target of $39, while several institutional investors recently initiated positions.
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 23,463 shares of Artiva Biotherapeutics stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $7.20, for a total transaction of $168,933.60. Following the completion of the sale, the chief executive officer owned 1,519,606 shares in the company, valued at $10,941,163.20. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Fred Aslan also recently made the following trade(s):
- On Monday, October 5th, Fred Aslan sold 61,696 shares of Artiva Biotherapeutics stock. The stock was sold at an average price of $6.84, for a total transaction of $422,000.64.
- On Tuesday, September 8th, Fred Aslan sold 23,429 shares of Artiva Biotherapeutics stock. The stock was sold at an average price of $10.92, for a total transaction of $255,844.68.
Artiva Biotherapeutics Price Performance
Shares of NASDAQ ARTV opened at $7.00 on Thursday. The business has a 50-day moving average of $9.96 and a 200-day moving average of $9.24. Artiva Biotherapeutics, Inc. has a fifty-two week low of $2.71 and a fifty-two week high of $14.53. The stock has a market capitalization of $342.23 million, a price-to-earnings ratio of -2.12 and a beta of 2.40.
Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.63). On average, sell-side analysts expect that Artiva Biotherapeutics, Inc. will post -2.62 EPS for the current year.
Key Stories Impacting Artiva Biotherapeutics
Here are the key news stories impacting Artiva Biotherapeutics this week:
- Positive Sentiment: Analyst support remains strong: Cantor Fitzgerald maintained an “overweight” rating with a $40 price target, while HC Wainwright reiterated a “buy” rating. The reported consensus rating is “Moderate Buy,” with an average target of $39, substantially above recent trading levels.
- Positive Sentiment: Several institutions, including State of Wyoming, Squarepoint Ops, Spark Investment Management, Dimensional Fund Advisors and Sanctuary Advisors, recently initiated positions in ARTV. These purchases may provide incremental institutional support. Artiva Biotherapeutics institutional ownership report
- Neutral Sentiment: Artiva is a clinical-stage biotechnology company developing off-the-shelf natural killer-cell therapies. Its lead product, AlloNK (AB-101), is being tested with rituximab for autoimmune diseases such as systemic lupus erythematosus and lupus nephritis. The company remains unprofitable, and analysts expect a full-year loss.
- Negative Sentiment: CEO Fred Aslan sold 23,463 shares for approximately $168,934 on October 6, reducing his direct holdings by 1.52%. This followed his sale of 61,696 shares, worth approximately $422,001, on October 5.
- Negative Sentiment: COO Jennifer Bush sold 8,370 shares, while insiders Christopher Horan and Subhashis Banerjee sold 10,340 and 1,099 shares, respectively. The reported sales by Bush, Aslan and other insiders were made to cover tax withholding obligations tied to vested equity awards, which makes them less bearish than discretionary selling but can still weigh on sentiment. Artiva Biotherapeutics insider selling report
Institutional Investors Weigh In On Artiva Biotherapeutics
Several hedge funds have recently added to or reduced their stakes in ARTV. State of Wyoming acquired a new position in shares of Artiva Biotherapeutics in the second quarter valued at approximately $45,000. Squarepoint Ops LLC acquired a new stake in Artiva Biotherapeutics during the 2nd quarter worth approximately $144,000. Spark Investment Management LLC acquired a new stake in Artiva Biotherapeutics during the 2nd quarter worth approximately $160,000. Dimensional Fund Advisors LP bought a new stake in Artiva Biotherapeutics in the 1st quarter valued at $131,000. Finally, Sanctuary Advisors LLC bought a new stake in Artiva Biotherapeutics in the 1st quarter valued at $139,000.
Analyst Upgrades and Downgrades
ARTV has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $40.00 price target on shares of Artiva Biotherapeutics in a research note on Friday, October 2nd. HC Wainwright reaffirmed a "buy" rating on shares of Artiva Biotherapeutics in a report on Friday, October 2nd. Wall Street Zen upgraded shares of Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $39.00.
View Our Latest Stock Analysis on Artiva Biotherapeutics
About Artiva Biotherapeutics
(
Get Free Report)
Artiva Biotherapeutics, Inc (NASDAQ:ARTV) is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company's approach is designed to produce off-the-shelf cell therapies that can be manufactured at scale and administered without using cells collected from each individual patient.
Artiva's lead investigational product, AlloNK, also known as AB-101, is an allogeneic NK cell therapy being evaluated in combination with rituximab for autoimmune conditions, including systemic lupus erythematosus and lupus nephritis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
